BACK

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19:

This report analyzed data on 8910 patients with COVID – 19 from the International Surgical Outcomes Collaborative (Surgisphere) Registry including 169 hospitals located in 11 countries from Asia, Europe and North America. Overall 515 patients died (5.8%) in hospital, while 8395 survived to discharge.

Key Points:

  • Background

Existing patient characteristics independently associated with in-hospital mortality (shown as % with and without the condition) include:

  • Demographics
    • Age greater than 65 years (10.0 vs. 4.9%)
    • Male sex (6.3 vs. 5.0%)
  • Cardiovascular risks
    • Coronary Artery Disease (10.2% vs. 5.2%)
    • Heart Failure (15.3 vs. 5.6%)
    • Cardiac Arrhythmia (11.5 vs. 5.6%)
  • Pulmonary
    • COPD (14.2% vs. 5.6%)
    • Current Smokers (9.4% vs. 5.6%)
  • CV Treatment
    • Statins (4.2% on vs. 6% not on – favorable)
    • ACE/ARB overall safety (ACE 2.1% on vs. 6.1% not on – favorable; ARB 6.8% on vs. 5.7% off – neutral).
  • Summary

This study reaffirms the significant increased mortality risk for patients with cardiovascular disease or risk factors and importantly, supports prior retrospective reviews regards the safety of ACE/ARB treatment